Obesity epidemic results in Non-Alcoholic Fatty Liver Disease (NAFLD) becoming the most common cause of liver disease in Europe.
World´s leading experts gather in Seville to discuss the fastest growing health epidemic in Europe now affecting 1 in 4 people. 26 September 2019 – Seville, Spain The Non-Alcoholic Fatty Liver Disease…
Why fatty liver disease could be the next public health crisis
Is non-alcoholic fatty liver disease the next public health crisis? After singer George Michael passed away in 2016, the coroner's report listed fatty liver disease as one of the causes of death.…
ELPA announces ELPA Pre-Summit on NAFLD
"Save the date! ELPA announces ELPA Pre-Summit on NAFLD – information for and from patients, patient experiences and views on NAFLD, as a back to back event to EASL NAFLD Summit on…
Ultrasound modules 3 and 4 now available on EASL Campus
Modules 3 and 4 of the EASL/EFSUMB Ultrasound of the Liver course are now available on EASL Campus. Module 3 – Focal liver lesions; the liver and biliary system Course description: The…
EASL equality, diversity and inclusion policy statement
EASL’s goal is to pursue and facilitate excellence in liver research, clinical practice of liver disorders, and the provision of education to all those interested in hepatology. This requires recognizing and supporting…
New online course on EASL Campus – HCC: Management of the side effects of immune checkpoint inhibitors
The HCC: Management of the side effects of immune checkpoint inhibitors course* is now available on EASL Campus. Course description : In this fascinating discussion, four of the leading experts in the field…
Survey: Lancet-EASL Commission on the care of liver cancer patients in Europe
The Lancet-EASL Commission is tackling liver diseases in Europe and overcoming unmet needs, stigma and inequities. The Commission is quantifying the burden of liver disease in Europe and addressing optimal diagnosis and…